Option chain shows key data for Revive Therapeutics's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Revive Therapeutics.

Revive Therapeutics (OTC:RVVTF) Stock, Option Chain

Revive Therapeutics Ltd is focused on the research, development, and commercialization of novel psychedelic and cannabinoid-based life sciences products and drug repurposing for infectious diseases. The firm's technology is being developed to fill the medical needs for diseases and disorders such as pain, inflammation, and wound care. Currently, the Company is exploring the use of Bucillamine for the potential treatment of public health medical emergencies and rare inflammatory disorders. Revive is also advancing the development of Psilocybin-based therapeutics through various program.

image006

Cannabis

Psychedelics

Exclusives

ATAI

CMPS

CSE:HAVN

CSE:TRIP

CYBN

HAVLF

MNMD

MYDECINE INNOV GRP by MYDECINE INNOVATIONS GROUP INC.

MYCOF

RVVTF

SEEL

TRIP

RED LIGHT HOLLAND CORP by Red Light Holland Corp.

TRUFF

Jamaica introduces its first legal psilocybin products in pharmacies through a historic partnership between PATOO and Fontana Pharmacy.

EXCLUSIVE: Legal Magic Mushroom Products Will Be Sold In Jamaica As Psilocybin Products Hit Pharmacy Shelves

News

Penny Stocks

Events

Markets

IGXT

NUMIF

PHRRF

SILO

Canadian Patients Demand Access To Psilocybin: Federal Lawsuit, Official Petition &amp; Failing Mechanism

A patient-led lawsuit against the Canadian government is claiming access to therapeutic psilocybin is a constitutional right under the Canadian Charter of Rights and Freedoms.

Psyched: Canada&#39;s Case For Psilocybin Access And Microdose Trial, US Reform Update, Battle With DEA &amp; More

Specialty drug delivery technology biopharma company Revive Therapeutics Ltd. (OTCQB: RVVTF) is undertaking research and development activities for its proprietary transdermal microneedle patch to deliver MDMA toward IND-enabling studies, supported by an exclusive supply deal with PharmaAla Biotech Holdings Inc.

MDMA Transdermal Patch Moves Toward First-In-Human Trials: Latest Development Update

REVIVE THERAPEUTICS LTD by Revive Therapeutics Ltd.

Revive Therapeutics Ltd

Cantor Fitzgerald analyst Matthew Prisco maintains Micron Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>) with a Overweight and lowers the price target from $150 to $130.

Price Target

Analyst Ratings

Cantor Fitzgerald Maintains Overweight on Micron Technology, Lowers Price Target to $130

B. Riley Securities analyst Hal Goetsch reiterates Sezzle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEZL#NASDAQ">SEZL</a>) with a Buy and raises the price target from $353 to $372.

Reiteration

SEZL

B. Riley Securities Reiterates Buy on Sezzle, Raises Price Target to $372

Shares of Oklo Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OKLO#NYSE">OKLO</a>) were climbing in early trading on Thursday, after the nuclear startup announced <a href="https://www.benzinga.com/24/12/42554232/oklo-stock-is-surging-wednesday-morning-whats-going-on">a long-term agreement with Switch</a>.
The company's business model positions it in a "solid spot" for long-term recurring revenues, according to Wedbush.
<a href="https://www.benzinga.com/analyst-stock-ratings/analyst/5e00ad4e3513fb0001f03cfd/daniel-ives">Analyst Daniel Ives</a> initiated coverage of Oklo with an Outperform rating and a price target of $26.
Ives noted the company&#8217;s unique business, which brings small modular reactors (SMRs) directly to its customers.
Check out <a href="https://www.benzinga.com/analyst-stock-ratings">other analyst stock ratings</a>.
Oklo, backed by OpenAI CEO Sam Altman, has a differentiated business model in that it "sells power, not the reactors, directly to customers under long-term contracts which in turn provide long-term recurring revenues and a streamlined regulatory pathway," the analyst stated.
The company aims to develop its first SMR by 2027, which will be a fast fission reactor that is cooled by liquid metal sodium, with HALEU (High-Assay Low-Enriched Uranium) as a fuel, "which has proven itself as a superior fuel to traditional LEU for its ability to generate further power over time while minimizing waste," he added.
"The AI Revolution is driving significant demand for clean energy to power AI initiatives with necessary computing power expected to grow 10x by 2030 putting OKLO is a great position to capitalize on this elevated demand," Ives further wrote.
Price Action: Shares of Oklo had risen by 2.4% to $18.80 at the time of publication on Thursday.
Read More: 
<ul>
<li><a href="https://www.benzinga.com/content/42531058/is-it-time-to-buy-nuclear-energy-stocks-after-the-latest-dip">Is It Time to Buy Nuclear Energy Stocks After the Latest Dip?</a></li>
</ul>
Image: Courtesy of Oklo, Inc.

Analyst Color

Long Ideas

Initiation

Movers

Trading Ideas

OKLO

Oklo Business Model Supports Recurring Revenues, AI Revolution Creates Elevated Demand

On Thursday, Prothena Corporation plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTA#NASDAQ">PRTA</a>) released results from the Phase 2b PADOVA study of prasinezumab in early-<a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/b42568873/roches-phase-iib-study-of-prasinezumab-missed-primary-endpoint-but-suggests-possible-clinical-bene" rel="noreferrer noopener">stage Parkinson&#8217;s disease</a>.
Partner Roche Holdings AG (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RHHBY#OTC">RHHBY</a>) conducted the 586-subject study investigating prasinezumab in early-stage Parkinson&#8217;s disease patients who had been treated for a minimum of 18 months while on stable symptomatic treatment.
Prasinezumab <a target="_blank" href="https://www.roche.com/media/releases/med-cor-2024-12-19" rel="noreferrer noopener">showed</a> a potential clinical effect in the primary endpoint of time to confirmed motor progression with an HR=0.84 and p=0.0657, missing statistical significance.
The companies said the effect of prasinezumab was more pronounced in a pre-specified analysis in the population treated with levodopa (75% of participants), HR=0.79 and nominal p=0.0431.
Pre-specified supplementary covariate-adjusted analyses of these endpoints demonstrated nominally significant effects on the primary endpoint (HR=0.81; nominal p=0.0334) and in the levodopa subgroup (HR=0.76; nominal p=0.0175).
Consistent positive trends across multiple secondary and exploratory endpoints were also observed. Prasinezumab continues to be well tolerated, and no new safety signals were observed in the study.
The Phase 2 PASADENA and Phase 2b PADOVA open-label extension studies will continue to explore the observed effects in both studies.
Roche will continue to evaluate the data and work together with health authorities to determine the next steps.
Full results from the PADOVA study will be presented at an upcoming medical meeting.
Price Action: PRTA stock is up 32.40% at $15.83 at the last check on Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42561240/salesforces-ai-powered-agentforce-20-spurs-analyst-upgrades-and-growth-optimism" target="_blank" rel="noreferrer noopener">Wall Street Analysts Are Bullish On Salesforce&#8217;s AI Vision &#8211; Here&#8217;s Why</a></li>
</ul>

Biotech

Large Cap

Health Care

General

PRTA

RHHBY

Roche-Prothena Partnered Mid-Stage Parkinson's Trial Misses Primary Endpoint, But Cling On Signs Of Clinical Benefits

B. Riley Securities analyst Bryce Rowe maintains NewtekOne (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEWT#NASDAQ">NEWT</a>) with a Neutral and raises the price target from $13 to $14.

NEWT

B. Riley Securities Maintains Neutral on NewtekOne, Raises Price Target to $14

<a href="https://x.com/jonkarl/status/1869779884253249842" title="https://x.com/jonkarl/status/1869779884253249842">https://x.com/jonkarl/status/1869779884253249842</a>

Macro Economic Events

Politics

Economics

ABC Correspondent Jonathan Karl Posts On X: 'In a conversation a few minutes ago, @realDonaldTrump told me, "There won't be anything approved unless the debt ceiling is done with."'

Sonic, a gaming platform on the Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>) blockchain, and Injective, a Layer-1 blockchain, on Thursday announced a strategic partnership to develop what they claim to be the industry&#8217;s first cross-chain <a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42512673/ai-cryptocurrencies-surge-208-to-61-5-billion-market-cap-in-2024-these-were-the-top-performers">AI Agent platform.</a>
This initiative, dubbed the Smart Agent Hub, aims to merge the capabilities of Solana and Injective, creating a synergistic environment for AI agent development across blockchain ecosystems.
The collaboration leverages Sonic&#8217;s HyperGrid technology to establish a dedicated Solana Virtual Machine (SVM) grid within Injective, facilitating direct communication between the Solana and Injective networks through the Inter-Blockchain Communication Protocol (IBC). 
This integration allows for the execution of Solana smart contracts on Injective, opening new possibilities for interoperability.
A key aspect of this venture is the bidirectional bridge that will support the seamless transfer of assets like SOL and Injective (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/inj/usd">INJ</a>) tokens, enhancing liquidity and user experience by allowing for both wrapped and native token transfers. 
This setup not only aims to simplify asset movement but also promises developers a unified experience, where they can deploy Solana-based applications onto Injective with ease.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42573095/bitcoin-reserve-could-call-us-solvency-into-question-critic-says-vaneck-exec-fires-back-this-is-loserthink">Bitcoin Reserve Could Call US Solvency Into Question Critic Says, VanEck Exec Fires Back: &#8216;This Is Loserthink&#8217;</a>
Eric Chen, CEO of Injective Labs, said, &#8220;This industry needs infrastructure that breaks down chain-specific barriers. Our joint effort with Sonic creates a foundation for developers to build applications that leverage the best of both Solana and Injective ecosystems. Together, we're laying the groundwork for what we believe will be one of the most significant AI-driven innovations in all of Web3.&#8221;
Speaking with Benzinga, Chris Zhu, Co-founder and CEO of Sonic acknowledged the complexities in state synchronization and cross-chain messaging but emphasized that Sonic&#8217;s existing HyperGrid infrastructure would be pivotal in addressing these issues. 
Zhu highlighted the strategic advantage of Sonic&#8217;s partnerships, particularly noting, &#8220;With over 10 games already deployed on Sonic&#8217;s network and numerous hackathon-incubated projects, we provide AI developers immediate access to a diverse gaming ecosystem ready to integrate AI agents.&#8221;
Asked about economic models and governance, Zhu outlined a system where gas fees on the Injective SVM grid would initially be in SOL, with a mechanism for revenues to be cycled back into the ecosystem through Injective's burn auction system. 
On governance, he mentioned a token-based model designed to protect against manipulation by large token holders, ensuring a democratic approach to decision-making.
This partnership is set to roll out its first phase in Q1 2025, with plans to integrate various sectors like gaming, DeFi, and social platforms into the Smart Agent Hub. 
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42561551/microstrategy-chairman-michael-saylor-eyes-intelligent-leverage-with-bitcoin-purchases">MicroStrategy Chairman Michael Saylor Eyes&#8217; Intelligent Leverage&#8217; With Bitcoin Purchases</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$INJ

$SOL

Sonic And Injective Pioneer Cross-Chain AI Agent Platform

Financial giants have made a conspicuous bullish move on Nike. Our analysis of options history for Nike (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>) revealed 30 unusual trades.
Delving into the details, we found 46% of traders were bullish, while 36% showed bearish tendencies. Out of all the trades we spotted, 15 were puts, with a value of $1,138,017, and 15 were calls, valued at $996,251.
<h3>Predicted Price Range</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $55.0 and $100.0 for Nike, spanning the last three months.
<h3>Volume &amp; Open Interest Development</h3>
In terms of liquidity and interest, the mean open interest for Nike options trades today is 5022.5 with a total volume of 16,626.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Nike's big money trades within a strike price range of $55.0 to $100.0 over the last 30 days.
<h3>Nike Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734625856_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>NKE</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/15/27</td>
<td>$5.25</td>
<td>$4.4</td>
<td>$4.75</td>
<td>$60.00</td>
<td>$475.0K</td>
<td>1.1K</td>
<td>1.0K</td>
</tr>
<tr>
<td>NKE</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$19.15</td>
<td>$18.8</td>
<td>$19.15</td>
<td>$60.00</td>
<td>$298.7K</td>
<td>309</td>
<td>158</td>
</tr>
<tr>
<td>NKE</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/15/27</td>
<td>$16.7</td>
<td>$15.25</td>
<td>$16.0</td>
<td>$77.50</td>
<td>$160.0K</td>
<td>5.0K</td>
<td>105</td>
</tr>
<tr>
<td>NKE</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/19/25</td>
<td>$11.0</td>
<td>$10.75</td>
<td>$10.75</td>
<td>$80.00</td>
<td>$113.9K</td>
<td>1.9K</td>
<td>31</td>
</tr>
<tr>
<td>NKE</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/18/26</td>
<td>$3.6</td>
<td>$3.3</td>
<td>$3.55</td>
<td>$55.00</td>
<td>$95.8K</td>
<td>1.2K</td>
<td>270</td>
</tr>
</tbody>
</table>

<h3>About Nike</h3>
Nike is the largest athletic footwear and apparel brand in the world. Key categories include basketball, running, and football (soccer). Footwear generates about two thirds of its sales. Its brands include Nike, Jordan (premium athletic footwear and clothing), and Converse (casual footwear). Nike sells products worldwide through company-owned stores, franchised stores, and third-party retailers. The firm also operates e-commerce platforms in more than 40 countries. Nearly all its production is outsourced to contract manufacturers in more than 30 countries. Nike was founded in 1964 and is based in Beaverton, Oregon.
In light of the recent options history for Nike, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Present Market Standing of Nike</h3>
<ul>
<li>With a volume of 4,064,598, the price of NKE is down -0.39% at $76.6. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 0 days.</li>
</ul>
<h3>What The Experts Say On Nike</h3>
Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $90.2.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Needham downgraded its action to Buy with a price target of $84. 
&#x2A; Maintaining their stance, an analyst from Evercore ISI Group continues to hold a Outperform rating for Nike, targeting a price of $97. 
&#x2A; An analyst from B of A Securities persists with their Buy rating on Nike, maintaining a target price of $95. 
&#x2A; An analyst from Deutsche Bank has decided to maintain their Buy rating on Nike, which currently sits at a price target of $82. 
&#x2A; An analyst from Telsey Advisory Group has decided to maintain their Outperform rating on Nike, which currently sits at a price target of $93. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Nike with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Options

What the Options Market Tells Us About Nike

Deep-pocketed investors have adopted a bearish approach towards Vistra (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VST#NYSE">VST</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in VST usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 16 extraordinary options activities for Vistra. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 31% leaning bullish and 50% bearish. Among these notable options, 6 are puts, totaling $224,668, and 10 are calls, amounting to $627,643.
<h3>What's The Price Target?</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $80.0 to $175.0 for Vistra over the recent three months. 
<h3>Insights into Volume &amp; Open Interest</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Vistra's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Vistra's significant trades, within a strike price range of $80.0 to $175.0, over the past month.
<h3>Vistra Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734625851_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>VST</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$2.1</td>
<td>$1.55</td>
<td>$1.9</td>
<td>$170.00</td>
<td>$214.9K</td>
<td>4.5K</td>
<td>1.1K</td>
</tr>
<tr>
<td>VST</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$16.6</td>
<td>$16.2</td>
<td>$16.2</td>
<td>$160.00</td>
<td>$77.7K</td>
<td>641</td>
<td>49</td>
</tr>
<tr>
<td>VST</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$4.7</td>
<td>$4.5</td>
<td>$4.5</td>
<td>$170.00</td>
<td>$65.2K</td>
<td>209</td>
<td>146</td>
</tr>
<tr>
<td>VST</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$3.7</td>
<td>$3.1</td>
<td>$3.4</td>
<td>$155.00</td>
<td>$60.1K</td>
<td>4.8K</td>
<td>225</td>
</tr>
<tr>
<td>VST</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$38.6</td>
<td>$38.5</td>
<td>$38.5</td>
<td>$175.00</td>
<td>$57.7K</td>
<td>32</td>
<td>15</td>
</tr>
</tbody>
</table>

<h3>About Vistra</h3>
Vistra Energy is one of the largest power producers and retail energy providers in the us Following the 2024 Energy Harbor acquisition, Vistra owns 41 gigawatts of nuclear, coal, natural gas, and solar power generation along with one of the largest utility-scale battery projects in the world. Its retail electricity business serves 5 million customers in 20 states, including almost a third of all Texas electricity consumers. Vistra emerged from the Energy Future Holdings bankruptcy as a stand-alone entity in 2016. It acquired Dynegy in 2018.
Following our analysis of the options activities associated with Vistra, we pivot to a closer look at the company's own performance.
<h3>Current Position of Vistra</h3>
<ul>
<li>Currently trading with a volume of 1,948,136, the VST's price is up by 1.35%, now at $134.68. </li>
<li>RSI readings suggest the stock is currently may be approaching oversold.</li>
<li>Anticipated earnings release is in 69 days.</li>
</ul>
<h3>Expert Opinions on Vistra</h3>
Over the past month, 1 industry analysts have shared their insights on this stock, proposing an average target price of $169.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from Morgan Stanley continues to hold a Overweight rating for Vistra, targeting a price of $169. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Vistra with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Vistra's Options: A Look at What the Big Money is Thinking

High-rolling investors have positioned themselves bearish on Archer Aviation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACHR#NYSE">ACHR</a>), and it's important for retail traders to take note. 
\This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in ACHR often signals that someone has privileged information.
Today, Benzinga's options scanner spotted 11 options trades for Archer Aviation. This is not a typical pattern.
The sentiment among these major traders is split, with 27% bullish and 54% bearish. Among all the options we identified, there was one put, amounting to $30,800, and 10 calls, totaling $350,395.
<h3>What's The Price Target?</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $3.0 to $11.0 for Archer Aviation over the last 3 months. 
<h3>Volume &amp; Open Interest Trends</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Archer Aviation's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Archer Aviation's significant trades, within a strike price range of $3.0 to $11.0, over the past month.
<h3>Archer Aviation Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734625845_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACHR</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$2.6</td>
<td>$2.5</td>
<td>$2.5</td>
<td>$8.00</td>
<td>$52.7K</td>
<td>6.6K</td>
<td align="right">385</td>
</tr>
<tr>
<td>ACHR</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$1.95</td>
<td>$0.0</td>
<td>$1.95</td>
<td>$11.00</td>
<td>$39.0K</td>
<td>0</td>
<td align="right">200</td>
</tr>
<tr>
<td>ACHR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$3.8</td>
<td>$3.7</td>
<td>$3.76</td>
<td>$10.00</td>
<td>$38.2K</td>
<td>13.7K</td>
<td align="right">176</td>
</tr>
<tr>
<td>ACHR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$3.8</td>
<td>$3.6</td>
<td>$3.6</td>
<td>$10.00</td>
<td>$37.0K</td>
<td>13.7K</td>
<td align="right">179</td>
</tr>
<tr>
<td>ACHR</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$3.6</td>
<td>$3.4</td>
<td>$3.5</td>
<td>$5.00</td>
<td>$35.0K</td>
<td>33.1K</td>
<td align="right">9</td>
</tr>
</tbody>
</table>

<h3>About Archer Aviation</h3>
Archer Aviation Inc advances the benefits of sustainable air mobility. The company is engaged in designing and developing a fully electric vertical takeoff and landing eVTOL aircraft for use in UAM networks. It is creating an electric airline that moves people throughout cities in a quick, safe, sustainable, and cost-effective manner.
<h3>Where Is Archer Aviation Standing Right Now?</h3>
<ul>
<li>Trading volume stands at 31,852,126, with ACHR's price up by 1.79%, positioned at $9.11.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 67 days.</li>
</ul>
<h3>What The Experts Say On Archer Aviation</h3>
A total of 4 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $12.875.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Canaccord Genuity has decided to maintain their Buy rating on Archer Aviation, which currently sits at a price target of $11. 
&#x2A; Consistent in their evaluation, an analyst from Cantor Fitzgerald keeps a Overweight rating on Archer Aviation with a target price of $13. 
&#x2A; Maintaining their stance, an analyst from Deutsche Bank continues to hold a Buy rating for Archer Aviation, targeting a price of $15. 
&#x2A; Consistent in their evaluation, an analyst from HC Wainwright &amp; Co. keeps a Buy rating on Archer Aviation with a target price of $12. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Archer Aviation with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

ACHR

Archer Aviation Unusual Options Activity

At Berkshire Hathaway&#8217;s 2023 annual <a href="https://www.youtube.com/watch?v=UKw_NjWtg5w">meeting</a>, Charlie Munger–Warren Buffett's longtime business partner – once again shared <a href="https://www.benzinga.com/personal-finance/24/04/38220646/charlie-munger-told-a-table-full-of-people-all-the-ways-tesla-would-fail-elon-musk-said-it-made-">his thoughts on Elon Musk</a>, the billionaire CEO behind Tesla, SpaceX and Starlink. When asked if he still believes Musk "overestimates himself, &#8221; Munger didn&#8217;t hold back."
His answer? Yes, Elon Musk does overestimate himself. But Munger quickly followed that up with an important acknowledgment: Musk is very talented, which is part of the reason for his success.
Don't Miss:
<ul>
<li>The global games market is projected to generate $272B by the end of the year —<a href="https://www.benzinga.com/money/gameflip"> for $0.55/share, this VC-backed startup with a 7M+ userbase gives investors easy access to this asset market.</a></li>
<li>Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/mode-mobile-2">The deadline to invest and receive your shares this year is 12/20. Join 30,000+ shareholders and invest at $0.26/share today.</a></li>
</ul>
Munger pointed out that Musk's boldness and relentless drive to achieve the "impossible" have been key to his extraordinary accomplishments. He even credited Musk's success to a single word: fanaticism.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Warren Buffett today on <a href="https://twitter.com/elonmusk?ref_src=twsrc%5Etfw">@elonmusk</a>: There&#39;s this Bill Maher program, he interviews Elon. Elon does a terrific job toe to toe with Bill Maher. It&#39;s worth watching. Elon is a brilliant guy; He dreams about things and his dream have got a foundation. Munger: He likes taking on the… <a href="https://t.co/s8NdiI5WcL">pic.twitter.com/s8NdiI5WcL</a>
&mdash; Sawyer Merritt (@SawyerMerritt) <a href="https://twitter.com/SawyerMerritt/status/1654964707789266946?ref_src=twsrc%5Etfw">May 6, 2023</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
<h2 class="wp-block-heading">"Unreasonably Extreme Objectives"</h2>
Munger noted that Musk's tendency to take on incredibly ambitious goals – goals most people would dismiss as impossible – sets him apart. "He would not have achieved what he has in life if he hadn't tried for unreasonably extreme objectives," Munger explained.
This doesn't mean Munger wants to follow the same path, though. He clarified that his approach to business and life differs greatly from Musk's. Munger said, &#8220;We&#8217;re looking for the easy job,&#8221; alluding to his and Buffett&#8217;s penchant for low-risk, attainable endeavors.
See Also: Can you guess how many Americans successfully retire with $1,000,000 saved?<a href="https://www.benzinga.com/money/1milsaved"> The percentage may shock you</a>.
Buffett added that although Musk&#8217;s &#8220;fanatic dedication&#8221; to solving the impossible is great, neither he nor Munger would like the lifestyle. "It takes over your life," Buffett said. "And I just like the way I'm living."
<h2 class="wp-block-heading">Not the First Time Munger Has Commented on Musk</h2>
This isn't the first time Munger has addressed Musk's unique approach. Over the years, he's shared both admiration and skepticism about the tech entrepreneur.
In 2018, Munger described Musk as "bold and brilliant" but noted that taking big swings can result in either "remarkable results" or "quick failures."
In 2019, at the Daily Journal Corp's annual <a href="https://www.youtube.com/watch?v=T_ZUhnv1Qqw">meeting</a>, <a href="https://www.benzinga.com/news/23/06/33019697/billionaire-investor-charlie-munger-playfully-jabs-elon-musks-overestimated-iq-deeming-him-unsuitabl">Munger took a lighthearted shot</a> at Musk. When a shareholder mentioned Munger's idea about preferring someone with an IQ of 130 who thinks it's 120 over someone with an IQ of 150 who thinks it's 170, Munger smiled and said, "You must be thinking about Elon Musk." The crowd laughed, but Munger followed up with a key observation:
Trending: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"> you can become an investor for $0.80 per share today.</a>
"Never underestimate the man who overestimates himself. These weird guys who overestimate themselves occasionally knock it right out of the park."
At the 2023 meeting, Munger and Buffett clarified that while they respect Musk's achievements, they wouldn't trade places with him. Buffett said, "We don't want to compete with Elon," admitting that Musk's relentless work ethic and high-stakes goals aren't for everyone.
Musk himself has acknowledged the toll his approach takes. In interviews, he's spoken about the stress, sleepless nights and personal sacrifices involved in running companies like Tesla and SpaceX.
It would be interesting to know what they think about <a href="https://www.benzinga.com/general/sports/24/12/42521401/elon-musk-is-so-rich-he-could-buy-every-mlb-nba-nfl-nhl-team-and-still-have-cash-left-over">Musk&#8217;s recent meteoric political rise</a>, during which, again, he was teetering between "remarkable results" and "quick failures."
Read Next:
<ul>
<li>Deloitte's fastest-growing software company partnered with Amazon, Walmart &amp; Target announces the deadline to invest this year is 12/20. – <a href="https://www.benzinga.com/money/mode-mobile-2">Last Chance to get 4,000 of its pre-IPO shares for just $0.26/share!</a></li>
<li>Can you guess how many retire with a $5,000,000 nest egg? <a href="https://www.benzinga.com/money/5mil-nest-egg-adv">The percentage may shock you</a>.</li>
</ul>

Even in 2023, Charlie Munger Said 'Elon Musk Overestimates Himself' But Credited His Success to One Key Factor

Centene (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) has outperformed the market over the past 15 years by 5.53% on an annualized basis producing an average annual return of 17.18%. Currently, Centene has a market capitalization of $30.04 billion. 
Buying $1000 In CNC: If an investor had bought $1000 of CNC stock 15 years ago, it would be worth $10,701.64 today based on a price of $59.50 for CNC at the time of writing.
<h3>Centene's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734625810_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Centene Stock In The Last 15 Years

B. Riley Securities analyst Lucas Pipes maintains MARA Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MARA#NASDAQ">MARA</a>) with a Neutral and raises the price target from $21 to $23.

MARA

B. Riley Securities Maintains Neutral on MARA Holdings, Raises Price Target to $23

Cantor Fitzgerald analyst Troy Jensen initiates coverage on Ranpak Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PACK#NYSE">PACK</a>) with a Overweight rating and announces Price Target of $11.5.

PACK

Cantor Fitzgerald Initiates Coverage On Ranpak Hldgs with Overweight Rating, Announces Price Target of $11.5

SoundHound AI Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOUN#NASDAQ">SOUN</a>) shares are trading lower by 12.9% to $18.16 during Thursday&#8217;s session. The stock may be experiencing a pullback due to profit-taking after a 47% surge over the past week and a remarkable 213% gain over the past month, driven by <a href="https://www.benzinga.com/news/24/12/42507758/whats-going-on-with-soundhound-ai-stock">key business updates</a>.
What To Know: SoundHound develops conversational AI using natural language processing (NLP) and large language models. Its solutions enhance customer experiences and operations in sectors like healthcare and quick-service restaurants.
The company's Amelia Conversational AI Platform was recognized as a leader in Frost &amp; Sullivan's 2024 Frost Radar for Healthcare AI. Analysts <a href="https://www.benzinga.com/pressreleases/24/12/b42461221/soundhound-ais-amelia-platform-recognized-as-frost-radar-leader-in-enterprise-conversational-ai-in">praised</a> its innovative use of NLP for improving patient engagement and administrative processes. SoundHound says the company&#8217;s acquisition of Amelia strengthens its position in a healthcare AI market projected to reach $2.34 billion by 2027.
SoundHound also recently <a href="https://www.benzinga.com/pressreleases/24/12/b42437440/soundhound-ai-supports-churchs-texas-chicken-to-power-voice-ai-ordering-at-the-drive-thru">partnered</a> with Church's Texas Chicken to implement voice AI in drive-thru operations, showcasing its expanding commercial applications.
&#8220;Integrating our technology into Church&#8217;s Texas Chicken restaurants marks a significant milestone in drive-thru innovation,&#8221; said&nbsp;James Hom, Chief Product Officer at SoundHound AI.
Read Also: <a href="https://www.benzinga.com/trading-ideas/technicals/24/12/42509206/soundhound-ai-soars-over-700-short-squeeze-potential-has-traders-talking">SoundHound AI Soars Over 700%: Short Squeeze Potential Has Traders Talking</a>
<h2 class="wp-block-heading">How To Buy SOUN Stock</h2>
By now you're likely curious about how to participate in the market for SoundHound AI &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy ‘fractional shares,' which allows you to own portions of stock without buying an entire share. For example, some stock, like Berkshire Hathaway, can cost thousands of dollars to own just one share. However, if you only want to invest a fraction of that, brokerages will allow you to do so.
In the the case of SoundHound AI, which is trading at $20.7 as of publishing time, $100 would buy you 4.83 shares of stock.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to ‘go short' a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, SOUN has a 52-week high of $24.08 and a 52-week low of $1.62.

SOUN

What's Going On With SoundHound AI Stock?

B. Riley Securities analyst Lucas Pipes maintains IREN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IREN#NASDAQ">IREN</a>) with a Buy and raises the price target from $15 to $16.

IREN

B. Riley Securities Maintains Buy on IREN, Raises Price Target to $16

On Thursday, FactSet Research Systems Inc&nbsp;(NYSE:&nbsp;FDS) reported first-quarter 2025 sales growth of 4.9% year-on-year to $568.7 million, beating the&nbsp;analyst&nbsp;consensus estimate of $565.13 million.&nbsp;
Organic&nbsp;revenues grew by 4.7% year over year to $567.7 million during the first quarter of fiscal 2025.
Growth in GAAP and Organic revenues this quarter was driven by wealth, asset owners, <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/g42572464/factset-reports-results-for-first-quarter-2025" rel="noreferrer noopener">and institutional asset managers</a>.
Adjusted EPS of $4.37 beat the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">analyst consensus estimate of $4.26</a>.
Annual Subscription Value&nbsp;(ASV) was $2.27 billion. Organic ASV was $2.26 billion.
&#8220;We are off to a good start in fiscal 2025 and achieved solid operating performance through sustained cost discipline and execution against our growth initiatives and capital strategy,&#8221; said Helen Shan, FactSet&#8217;s CFO.
&#8220;As we enter our second quarter, we have a robust pipeline fueled by the strength of our diverse portfolio of innovative solutions that deliver value and resonate with our clients,&#8221; said Phil Snow, CEO of FactSet.&nbsp;
Adjusted operating margin remained consistent at 37.6%.&nbsp;EBITDA increased 5% to $229.86 million
Client count as of November&nbsp;30, 2024 was 8,249, a net increase of 32 clients in the past three months, driven by an increase in partners, private equity and venture capital and wealth. The count includes clients with ASV of $10,000 and more.
The user count increased by 1,886 to 218,267 in the past three months, primarily due to an increase in wealth management users.
Annual ASV retention was greater than 95%. When expressed as a percentage of clients, annual retention was 91%.
FY25 Outlook:&nbsp;FactSet&nbsp;reaffirms its <a target="_blank" href="https://www.benzinga.com/news/earnings/24/09/40936160/factset-research-q4-earnings-revenue-and-profit-beat-adds-188-new-clients-margin-boost-and-more" rel="noreferrer noopener">fiscal 2025 outlook</a>. The company expects revenue of $2.285 billion—$2.305 billion, versus the $2.301 billion estimate, and adjusted EPS of $16.80–$17.40, versus&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">the consensus of $17.17</a>.
Organic ASV is expected to grow between $90 million and $140 million during fiscal 2025, with an adjusted operating margin guidance of 36.0%- 37.0%.
Price Action: FDS stock is up 0.60% at $475.88 at the last check on Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/12/42591703/fuelcell-energy-q4-revenue-surges-120-backlog-climbs-13-but-losses-persist-amid-restructuring-efforts" target="_blank" rel="noreferrer noopener">FuelCell Energy Q4 Revenue Surges 120%, Backlog Climbs 13%, But Losses Persist Amid Restructuring Efforts</a></li>
</ul>

Earnings

Guidance

Tech

FactSet Beats Q1 Earnings On Higher Subscriptions, Sticks to Annual Guidance

Cantor Fitzgerald analyst Troy Jensen initiates coverage on Cognex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGNX#NASDAQ">CGNX</a>) with a Overweight rating and announces Price Target of $49.

CGNX

Cantor Fitzgerald Initiates Coverage On Cognex with Overweight Rating, Announces Price Target of $49

B. Riley Securities analyst Mayank Mamtani upgrades Cognition Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGTX#NASDAQ">CGTX</a>) from Neutral to Buy and raises the price target from $1 to $1.5.

Upgrades

CGTX

B. Riley Securities Upgrades Cognition Therapeutics to Buy, Raises Price Target to $1.5

WIIM

Hims & Hers Health, Inc. Class A Common Stock

HIMS

Hims & Hers Health shares are trading lower after the FDA issued a new decision determining that the tirzepatide injection shortage is resolved.

Revive Therapeutics (TSE:RVV) has released an update. Revive Therapeutics Ltd. has announced positive feedback from the FDA regarding the developme...

Revive Therapeutics Advances Long COVID Treatment

Revive Therapeutics (TSE:RVV) has released an update. Revive Therapeutics Ltd. is advancing a study on Bucillamine as a potential treatment for ner...

Revive Therapeutics Tests Treatment for Nerve Agents

Revive Therapeutics (TSE:RVV) has released an update. Revive Therapeutics Ltd., a life sciences company, is conducting a study on Bucillamine for t...

Revive Therapeutics Explores Bucillamine for Nerve Agents and Viral Threats

Revive Therapeutics to focus on Bucillamine

Revive Therapeutics (TSE:RVV) has released an update. Revive Therapeutics is shifting its resources to focus on the development of Bucillamine for ...

Revive Therapeutics Prioritizes Bucillamine Development

Bright Minds rally ends as psychedelic stocks extend volatility

FDA is said to see "path forward" for ecstasy-based drug

Revive Therapeutics (RVVTF) announced an update on the research study evaluating Bucillamine as a potential treatment for nerve agent exposure, in ...

Revive Therapeutics provides update on research study of bucillamine

Massachusetts psychedelics legalization initiative poised to fail

Revive Therapeutics (TSE:RVV) has released an update. Revive Therapeutics has announced promising research showcasing psilocybin's potential as a t...

Comments

Revive Therapeutics

Revive Therapeutics (RVVTF) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga